What is HC Wainwright’s Estimate for RCUS Q3 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at HC Wainwright issued their Q3 2024 EPS estimates for shares of Arcus Biosciences in a report issued on Monday, October 21st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($1.05) per share for the quarter. HC Wainwright has a “Neutral” rating and a $20.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q4 2024 earnings at ($1.08) EPS, FY2024 earnings at ($3.20) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($5.39) EPS, FY2027 earnings at ($5.51) EPS and FY2028 earnings at ($2.52) EPS.

RCUS has been the topic of several other reports. Barclays cut their price target on shares of Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, July 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday, October 3rd. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $33.22.

Arcus Biosciences Trading Up 2.9 %

RCUS opened at $17.83 on Wednesday. The stock has a market capitalization of $1.63 billion, a P/E ratio of -5.77 and a beta of 0.88. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $20.31. The firm’s fifty day simple moving average is $16.89 and its 200 day simple moving average is $16.05.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, meeting the consensus estimate of ($1.02). The business had revenue of $39.00 million for the quarter, compared to analysts’ expectations of $26.24 million. Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The firm’s revenue was up 34.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.04) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in Arcus Biosciences by 51.6% in the 1st quarter. GAMMA Investing LLC now owns 2,427 shares of the company’s stock valued at $46,000 after buying an additional 826 shares during the last quarter. Headlands Technologies LLC acquired a new position in Arcus Biosciences in the 1st quarter valued at about $59,000. Innealta Capital LLC acquired a new position in Arcus Biosciences in the 2nd quarter valued at about $66,000. Point72 DIFC Ltd acquired a new position in Arcus Biosciences in the 2nd quarter valued at about $83,000. Finally, ProShare Advisors LLC grew its position in shares of Arcus Biosciences by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock worth $205,000 after purchasing an additional 746 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.